Compare · GILD vs PROK
GILD vs PROK
Side-by-side comparison of Gilead Sciences Inc. (GILD) and ProKidney Corp. (PROK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GILD and PROK operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- GILD is the larger of the two at $181.46B, about 317.6x PROK ($571.4M).
- Over the past year, GILD is up 31.5% and PROK is down 20.3% - GILD leads by 51.8 points.
- GILD has been more active in the news (10 items in the past 4 weeks vs 7 for PROK).
- GILD has more recent analyst coverage (25 ratings vs 13 for PROK).
- Company
- Gilead Sciences Inc.
- ProKidney Corp.
- Price
- $148.29+1.33%
- $1.83-2.92%
- Market cap
- $181.46B
- $571.4M
- 1M return
- +13.02%
- +18.06%
- 1Y return
- +31.54%
- -20.26%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1992
- 2021
- News (4w)
- 10
- 7
- Recent ratings
- 25
- 13
Gilead Sciences Inc.
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.
Latest GILD
- FDA Approval for SUNLENCA issued to GILEAD SCIENCES INC
- FDA Approval for SUNLENCA issued to GILEAD SCIENCES INC
- Director Welters Anthony exercised 18,000 shares at a strike of $61.06 and sold $2,675,220 worth of shares (18,000 units at $148.62) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form N-PX filed by Gilead Sciences Inc.
- Gilead Sciences to Present at Upcoming Third Quarter 2026 Investor Conferences
- European Commission Expands Role of Gilead’s Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer Across PD-L1 Status
- Director Bluestone Jeffrey exercised 5,000 shares at a strike of $67.04 and sold $725,078 worth of shares (5,000 units at $145.02) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Financial Officer Dickinson Andrew D sold $415,080 worth of shares (3,000 units at $138.36) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 165,646 units (SEC Form 4)
- Chief Comm & Corp Aff Officer Mercier Johanna exercised 25,000 shares at a strike of $67.07 and sold $3,853,908 worth of shares (28,000 units at $137.64) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 118,234 units (SEC Form 4)
- EVP Gen Counsel, Legal & Comp Cain Wettan Keeley M covered exercise/tax liability with 2,908 shares and converted options into 6,002 shares, increasing direct ownership by 58% to 8,454 units (SEC Form 4)
Latest PROK
- Director Pereira Brian Jg sold $1,067,773 worth of shares (757,164 units at $1.41), closing all direct ownership in the company (SEC Form 4)
- SEC Form 144 filed by ProKidney Corp.
- SEC Form 144 filed by ProKidney Corp.
- Amendment: SEC Form SCHEDULE 13G/A filed by ProKidney Corp.
- ProKidney Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SEC Form 10-Q filed by ProKidney Corp.
- ProKidney Reports Second Quarter 2026 Financial Results and Business Highlights
- Director Pereira Brian Jg converted options into 757,164 shares (SEC Form 4)
- SEC Form 4 filed by Chief Technical Officer Locke Kenneth Thomas
- Chief Legal Officer Girolamo Todd C converted options into 163,857 shares, increasing direct ownership by 100% to 327,713 units (SEC Form 4)